Search
Now showing items 41-45 of 45
Public preferences for delayed or immediate antibiotic prescriptions in UK primary care: A choice experiment.
(Public Library of Science (PLoS), 2021-08-01)
BACKGROUND: Delayed (or "backup") antibiotic prescription, where the patient is given a prescription but advised to delay initiating antibiotics, has been shown to be effective in reducing antibiotic use in primary care. ...
Preventative therapy for breast cancer: a clinical experience.
(SPRINGER, 2023-09-01)
BACKGROUND: Breast Cancer incidence in the UK is estimated to rise to 71,000 per year by 2035. Preventative strategies could significantly reduce this. Preventative therapy reduces women's risk of oestrogen receptor positive ...
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
(American Association for Cancer Research (AACR), 2024-01-05)
PURPOSE: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib ...
Racial and ethnic disparities in treatment-related heart disease mortality among US breast cancer survivors.
(OXFORD UNIV PRESS, 2023-03-01)
BACKGROUND: Racial and ethnic disparities in heart disease mortality by initial treatment type among breast cancer survivors have not been well described. METHODS: We included 739 557 women diagnosed with first primary ...
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
(MASSACHUSETTS MEDICAL SOC, 2021-06-24)
BACKGROUND: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with ...